Recurrent Pneumonia and History of Transplantation

  • Sonia de Arriba-MéndezEmail author
  • Eva Macías
  • Ignacio Dávila


  • Predominant antibody deficiencies are characterized by respiratory tract infections caused by encapsulated pyogenic bacteria

  • Prolonged hypogammaglobulinemia and associated infections have been reported as post-rituximab therapy complications

  • Most authors recommend to start IgG replacement when post-rituximab hypogammaglobulinemia is moderate or severe, although IgG antibody titers, infections, and patient’s risk factors should be considered


Hypogammaglobulinemia Rituximab Side effect 


  1. 1.
    Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: general considerations. In: Stiehm ER, Ochs HD, Winkelstein JA, editors. Immunologic disorders in infants and children. 5th ed. Philadelphia, PA: Saunders/Elsevier; 2004.Google Scholar
  2. 2.
    Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol. 2005;58(5):546–7.CrossRefGoogle Scholar
  3. 3.
    Erlewyn-Lajeunesse MD. Hyperimmunoglobulin-E syndrome with recurrent infection: a review of current opinion and treatment. Pediatr Allergy Immunol. 2000;11(3):133–41.CrossRefGoogle Scholar
  4. 4.
    Chiriaco M, Salfa I, Di Matteo G, Rossi P, Finocchi A. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects. Pediatr Allergy Immunol. 2016;27(3):242–53.CrossRefGoogle Scholar
  5. 5.
    Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy. 2011;9(1):10.CrossRefGoogle Scholar
  6. 6.
    Ballow M. Approach to the patient with recurrent infections. Clin Rev Allergy Immunol. 2008;34(2):129–40.CrossRefGoogle Scholar
  7. 7.
    Oliveira JB, Fleisher TA. Laboratory evaluation of primary immunodeficiencies. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S297–305.CrossRefGoogle Scholar
  8. 8.
    Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, Fraser GA, Lim W, Kelton JG. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.CrossRefGoogle Scholar
  9. 9.
    Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DR. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun. 2015;57:60–5.CrossRefGoogle Scholar
  10. 10.
    Nishio M, Fujimoto K, Yamamoto S, Endo T, Sakai T, Obara M, Kumano K, Minauchi K, Yamaguchi K, Takeda Y, Sato N, Koizumi K, Mukai M, Koike T. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol. 2006;77(3):226–32.CrossRefGoogle Scholar
  11. 11.
    Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum. 2008;58(1):5–14.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sonia de Arriba-Méndez
    • 1
    • 2
    Email author
  • Eva Macías
    • 2
    • 3
  • Ignacio Dávila
    • 2
    • 3
  1. 1.Pediatric ServiceUniversity Hospital of SalamancaSalamancaSpain
  2. 2.Faculty of Medicine, Department of Biologic and Diagnostics SciencesUniversity of SalamancaSalamancaSpain
  3. 3.Allergy ServiceUniversity Hospital of SalamancaSalamancaSpain

Personalised recommendations